FibroBiologics, Inc.
FBLG · XNASCIK 1958777fmd_155HPES0T6KNC357YH52B5HTZBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 15 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | 1 | 2 | 5 | 7 |
| Total operating expenses | 4 | 9 | 14 | 17 |
| Operating income | (4) | (9) | (14) | (17) |
| Interest expense | 1 | 0 | 0 | 0 |
| Interest and investment income | – | – | 0 | 0 |
| Other non-operating income (expense) | – | (0) | 3 | (2) |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (5) | (16) | (11) | (19) |
| Net income to common shareholders | (5) | (19) | (11) | – |